Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schuler

Showing results (231-240 of 251) with videos related to

Pageof 26
Sort By:
British Journal of Cancer|July 28, 2012
βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerD C Christoph, S Kasper, T C Gauler, et al.
Journal of Cancer Research and Clinical Oncology|July 13, 2022
The OUTREACH study: oncologists of German university hospitals in rotation on a palliative care unit-evaluation of attitude and competence in palliative care and hospiceT Biersching, A Schweda, K Oechsle, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2015
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomasH Reis, T Herold, S Ting, et al.
Journal of Cancer Research and Clinical Oncology|July 19, 2023
Impact of encorafenib on survival of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer in a real-world settingM Zurloh, M Goetz, T Herold, et al.
ESMO Open|August 21, 2022
Multimodal survival prediction in advanced pancreatic cancer using machine learningJ Keyl, S Kasper, M Wiesweg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2021
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaU Sahin, Ö Türeci, G Manikhas, et al.
ESMO Real World Data and Digital Oncology|April 3, 2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine careL Sellmann, D Marschner, U M Martens, et al.
ESMO Open|May 6, 2023
Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancerT M Reissig, I Tzianopoulos, S-T Liffers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II studyM Schuler, R Herrmann, J L De Greve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trialM Schuler, R Berardi, W-T Lim, et al.
Pageof 26

Showing results (231-240 of 251) with videos related to

Sort By:
Pageof 26
British Journal of Cancer|July 28, 2012
βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerD C Christoph, S Kasper, T C Gauler, et al.
Journal of Cancer Research and Clinical Oncology|July 13, 2022
The OUTREACH study: oncologists of German university hospitals in rotation on a palliative care unit-evaluation of attitude and competence in palliative care and hospiceT Biersching, A Schweda, K Oechsle, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2015
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomasH Reis, T Herold, S Ting, et al.
Journal of Cancer Research and Clinical Oncology|July 19, 2023
Impact of encorafenib on survival of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer in a real-world settingM Zurloh, M Goetz, T Herold, et al.
ESMO Open|August 21, 2022
Multimodal survival prediction in advanced pancreatic cancer using machine learningJ Keyl, S Kasper, M Wiesweg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2021
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaU Sahin, Ö Türeci, G Manikhas, et al.
ESMO Real World Data and Digital Oncology|April 3, 2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine careL Sellmann, D Marschner, U M Martens, et al.
ESMO Open|May 6, 2023
Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancerT M Reissig, I Tzianopoulos, S-T Liffers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II studyM Schuler, R Herrmann, J L De Greve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2020
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trialM Schuler, R Berardi, W-T Lim, et al.
Pageof 26